

Brand Name: Tezspire

Generic: tezepelumab

Type: monoclonal antibody

Year Accepted/Phase: 2021

Mechanism:

Tezepelumab targets and blocks TSLP, a cytokine that plays a key role in the initiation and persistence of airway inflammation in asthma. By blocking TSLP, tezepelumab reduces airway inflammation and improves asthma control.

Chemical Structure: N/A

Indication:

Tezspire is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older.

Clinical trials:

Clinical Trials for Severe Asthma

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/33979488/>

Purpose: Evaluate the efficacy and safety of tezepelumab in patients with severe asthma.

Dates: Clinical trials for Tezspire were conducted in the 2010s and early 2020s.

Results: These trials demonstrated that tezepelumab reduced the rate of asthma exacerbations, improved lung function, and reduced the need for oral corticosteroids in patients with severe asthma, including those with eosinophilic and non-eosinophilic phenotypes.

Impact: The positive results from these trials supported the approval of Tezspire for the treatment of severe asthma.